Relypsa pursues $126.5m IPO for patiromer
This article was originally published in Scrip
Executive Summary
Relypsa registered an initial public offering at the end of September in hopes of raising $126.5m to apply for US FDA approval of its hyperkalemia drug patiromer (RLY5016) and prepare for commercialization following recent positive Phase III data for the oral protein binder.